Company Overview

MapLight Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing precision medicines for central nervous system (CNS) and neuropsychiatric disorders. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on neuroscience-driven drug discovery and genetically informed therapeutics. Its core strategy centers on identifying biological mechanisms associated with severe psychiatric and neurological diseases and translating those findings into targeted therapeutics. Publicly available information indicates that the company’s lead development efforts have focused on schizophrenia and related neuropsychiatric conditions.

The company was founded in 2019 by researchers and biotechnology executives with expertise in neuroscience, genetics, and drug development. MapLight emerged from advances in human genetics and translational neuroscience, seeking to apply precision medicine approaches more commonly associated with oncology to psychiatric disorders. The company has positioned itself around the use of genetically validated targets, biomarker-informed clinical development, and neuroscience-focused therapeutic platforms intended to improve efficacy and patient selection in complex CNS diseases.

Business Operations

MapLight Therapeutics primarily operates through its internal neuroscience research and drug development programs. Its activities include target discovery, preclinical research, translational biology, biomarker development, and clinical-stage therapeutic advancement. Revenue generation has historically been tied to private financing activities, strategic collaborations, and investment capital rather than commercial product sales, as publicly available data indicates the company remains in the development stage. The company’s lead programs have involved therapies targeting glutamatergic signaling pathways and other mechanisms implicated in schizophrenia and neuropsychiatric disease biology.

Operations are centered in the United States, with research and development activities supported through collaborations with academic institutions, scientific advisors, and biotechnology partners. Public disclosures reference partnerships and licensing arrangements associated with neuroscience assets and platform technologies, although some details remain limited due to the company’s private status. Data inconclusive based on available public sources regarding the full scope of international operating infrastructure or material joint ventures.

Strategic Position & Investments

MapLight Therapeutics’ strategic direction has focused on advancing precision psychiatry through genetically informed CNS therapeutics. The company has emphasized biomarker-guided clinical development and patient stratification approaches designed to improve clinical outcomes in disorders where traditional psychiatric drug development has faced high failure rates. Its development strategy aligns with broader industry interest in neuroscience innovation and mechanism-based psychiatric therapies.

The company has raised substantial private financing from biotechnology-focused venture capital firms and healthcare investors to support clinical development and platform expansion. Publicly available information indicates investment support from major life sciences investment groups and participation from institutional biotechnology investors. MapLight has also pursued licensing and acquisition-related activities involving neuroscience compounds and intellectual property assets relevant to schizophrenia and CNS disorders. Data inconclusive based on available public sources regarding a broad portfolio of subsidiaries or independently operated portfolio companies.

Geographic Footprint

MapLight Therapeutics is headquartered in the United States, with principal operations in the biotechnology and life sciences sector concentrated in major U.S. research hubs. Its clinical and scientific activities primarily target the North American pharmaceutical and biotechnology ecosystem, including collaborations with U.S.-based research institutions, clinical investigators, and biotechnology investors.

Although the company’s operational footprint appears primarily domestic, its therapeutic development strategy addresses global CNS and psychiatric disease markets. Clinical development pathways and intellectual property positioning suggest potential future expansion into broader international pharmaceutical markets, including Europe and other major healthcare regions. Data inconclusive based on available public sources regarding material physical operations outside the United States.

Leadership & Governance

MapLight Therapeutics was founded by leaders in neuroscience, genetics, and biotechnology entrepreneurship. The company’s leadership philosophy has centered on applying precision medicine principles and translational neuroscience to psychiatric disease treatment, with an emphasis on rigorous biological validation and clinically actionable biomarkers.

Key executives and leadership figures include:

• David J. Hough, M.D. – Chief Executive Officer
• Taylor Schreiber, M.D., Ph.D. – Founder and President
• Katherine A. High, M.D. – Board member and biotechnology executive/advisor
• Peter Reinhart, Ph.D. – Scientific leadership and neuroscience advisor roles reported in public materials

Public information indicates the leadership team includes executives and advisors with prior experience at major biotechnology and pharmaceutical organizations focused on neuroscience, genetics, and drug commercialization. Some governance and executive details remain limited because the company is privately held and not subject to the same disclosure requirements as public companies.